Veer Bhavnagri - 15 Sep 2021 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
General Counsel
Signature
Veer Bhavnagri
Issuer symbol
ALLO
Transactions as of
15 Sep 2021
Net transactions value
-$112,494
Form type
4
Filing time
17 Sep 2021, 16:44:04 UTC
Previous filing
17 Aug 2021
Next filing
17 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Options Exercise $11,350 +5,000 +1.2% $2.27 426,669 15 Sep 2021 Direct F1
transaction ALLO Common Stock Sale $123,844 -5,000 -1.2% $24.77* 421,669 15 Sep 2021 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Options Exercise $0 -5,000 -4.3% $0.000000 112,300 15 Sep 2021 Common Stock 5,000 $2.27 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 316 shares of the Issuer's common stock acquired by the reporting person on September 15, 2021 pursuant to an employee stock purchase program.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.64 to $24.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.